Literature DB >> 34855459

Systemic Therapy Decision Making in Advanced Cancer: A Qualitative Analysis of Patient-Oncologist Encounters.

Garrett T Wasp1,2, Kristin E Knutzen3, Genevra F Murray4, Olivia C Brody-Bizar5, Matthew A Liu6, Kathryn I Pollak7, James A Tulsky8,9, Yael Schenker10, Amber E Barnato2,11,12.   

Abstract

PURPOSE: We sought to characterize patient-oncologist communication and decision making about continuing or limiting systemic therapy in encounters after an initial consultation, with a particular focus on whether and how oncologists foster shared decision making (SDM).
METHODS: We performed content analysis of outpatient oncology encounters at two US National Cancer Institute-designated cancer centers audio recorded between November 2010 and September 2014. A multidisciplinary team used a hybrid approach of inductive and deductive coding and theme development. We used a combination of random and purposive sampling. We restricted quantitative frequency counts to the coded random sample but included all sampled encounters in qualitative thematic analysis.
RESULTS: Among 31 randomly sampled dyads with three encounters each, systemic therapy decision making was discussed in 90% (84 of 93) encounters. Thirty-four (37%) broached limiting therapy, which 27 (79%) framed as temporary, nine (26%) as completion of a standard regimen, and five (15%) as permanent discontinuation. Thematic analysis of these 93 encounters, plus five encounters purposively sampled for permanent discontinuation, found that (1) patients and oncologists framed continuing therapy as the default, (2) deficiencies in the SDM process (facilitating choice awareness, discussing options, and incorporating patient preferences) contributed to this default, and (3) oncologists use persuasion rather than deliberation when broaching discontinuation.
CONCLUSION: In this study of outpatient encounters between patients with advanced cancer and their oncologists, when discussing systemic therapy, there exists a default to continue systemic therapy, and deficiencies in SDM contribute to this default.

Entities:  

Mesh:

Year:  2021        PMID: 34855459      PMCID: PMC9377707          DOI: 10.1200/OP.21.00377

Source DB:  PubMed          Journal:  JCO Oncol Pract        ISSN: 2688-1527


  41 in total

1.  Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups.

Authors:  Allison Tong; Peter Sainsbury; Jonathan Craig
Journal:  Int J Qual Health Care       Date:  2007-09-14       Impact factor: 2.038

2.  When the treatment goal is not cure: are cancer patients equipped to make informed decisions?

Authors:  Melina Gattellari; Katie J Voigt; Phyllis N Butow; Martin H N Tattersall
Journal:  J Clin Oncol       Date:  2002-01-15       Impact factor: 44.544

3.  Chemotherapy Use, Performance Status, and Quality of Life at the End of Life.

Authors:  Holly G Prigerson; Yuhua Bao; Manish A Shah; M Elizabeth Paulk; Thomas W LeBlanc; Bryan J Schneider; Melissa M Garrido; M Carrington Reid; David A Berlin; Kerin B Adelson; Alfred I Neugut; Paul K Maciejewski
Journal:  JAMA Oncol       Date:  2015-09       Impact factor: 31.777

4.  Communication Differences between Oncologists and Palliative Care Clinicians: A Qualitative Analysis of Early, Integrated Palliative Care in Patients with Advanced Cancer.

Authors:  Teresa Hagan Thomas; Vicki A Jackson; Heather Carlson; Simone Rinaldi; Angela Sousa; Andrea Hansen; Mihir Kamdar; Juliet Jacobsen; Elyse R Park; William F Pirl; Jennifer S Temel; Joseph A Greer
Journal:  J Palliat Med       Date:  2018-10-25       Impact factor: 2.947

5.  The content and amount of information given by medical oncologists when telling patients with advanced cancer what their treatment options are. palliative chemotherapy and watchful-waiting.

Authors:  C G Koedoot; F J Oort; R J de Haan; P J M Bakker; A de Graeff; J C J M de Haes
Journal:  Eur J Cancer       Date:  2004-01       Impact factor: 9.162

Review 6.  Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline.

Authors:  Timothy Gilligan; Nessa Coyle; Richard M Frankel; Donna L Berry; Kari Bohlke; Ronald M Epstein; Esme Finlay; Vicki A Jackson; Christopher S Lathan; Charles L Loprinzi; Lynne H Nguyen; Carole Seigel; Walter F Baile
Journal:  J Clin Oncol       Date:  2017-09-11       Impact factor: 44.544

7.  Deciding about (neo-)adjuvant rectal and breast cancer treatment: Missed opportunities for shared decision making.

Authors:  Marleen Kunneman; Ellen G Engelhardt; F L Laura Ten Hove; Corrie A M Marijnen; Johanneke E A Portielje; Ellen M A Smets; Hanneke J C J M Hanneke de Haes; Anne M Stiggelbout; Arwen H Pieterse
Journal:  Acta Oncol       Date:  2015-08-03       Impact factor: 4.089

8.  Patient involvement in decisions to limit treatment: the crucial role of agreement between physician and patient.

Authors:  Eva C Winkler; Stella Reiter-Theil; Dorothee Lange-Riess; Nina Schmahl-Menges; Wolfgang Hiddemann
Journal:  J Clin Oncol       Date:  2009-03-23       Impact factor: 44.544

9.  Discussing prognosis and treatment goals with patients with advanced cancer: A qualitative analysis of oncologists' language.

Authors:  Wen-Ying Sylvia Chou; Lauren M Hamel; Chan L Thai; David Debono; Robert A Chapman; Terrance L Albrecht; Louis A Penner; Susan Eggly
Journal:  Health Expect       Date:  2017-03-05       Impact factor: 3.377

10.  A three-talk model for shared decision making: multistage consultation process.

Authors:  Glyn Elwyn; Marie Anne Durand; Julia Song; Johanna Aarts; Paul J Barr; Zackary Berger; Nan Cochran; Dominick Frosch; Dariusz Galasiński; Pål Gulbrandsen; Paul K J Han; Martin Härter; Paul Kinnersley; Amy Lloyd; Manish Mishra; Lilisbeth Perestelo-Perez; Isabelle Scholl; Kounosuke Tomori; Lyndal Trevena; Holly O Witteman; Trudy Van der Weijden
Journal:  BMJ       Date:  2017-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.